Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...

The announcements reflect a calculated shift from discrete chip sales to integrated systems that address enterprise ...

In this video, Hamza Hassan, MD, assistant professor of oncology at Roswell Park Comprehensive Cancer Center, discusses the second-line of treatment for this case. Editor's note: The following is an ...

Jan. 18, 2026 A long-running Swedish study has followed adults for nearly five decades, uncovering when physical decline truly begins. Fitness and strength start slipping around age 35, then worsen ...